<DOC>
	<DOCNO>NCT02197221</DOCNO>
	<brief_summary>Phase III multicenter randomize , open-label study compare efficacy combine high dose chemotherapy use melphalan bortezomib versus melphalan alone follow stem cell transplant frontline multiple myeloma patient , non-progressive induction therapy .</brief_summary>
	<brief_title>Bortezomib-Melphalan Conditioning Regimen v Melphalan Frontline Transplant Eligible Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Must result initial diagnosis available time screen confirm follow : 1 . Diagnosis multiple myeloma accord diagnostic 2 . Symptomatic de novo Multiple Myeloma Be eligible highdose therapy autologous stem cell transplantation Autologous cell graft total number CD 34 cell &gt; = 5 X 106/kg freeze Progressive disease Females participant pregnant breastfeed A know infection human immunodeficiency virus An active viral hepatitis B C Unstable angina myocardial infarction within 4 month prior inclusion , heart failure NYHA class III IV angina , uncontrolled , history severe coronary artery disease , uncontrolled serious ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia conduction disturbance grade 3 unless patient pacemaker Uncontrolled hypertension uncontrolled diabetes within 14 day enrollment A history another malignancy . If cancer diagnose 10 year consider cure , authorization may request casebycase basis discussion principal investigator A significant neuropathy grade 34 grade 2 pain 14 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>